Hunter Syndrome Treatment Market to Grow with a CAGR of 5.02% through 2028
Government support, and the dedication of advocacy
groups are expected to drive the Global Hunter Syndrome Treatment Market growth
in the forecast period, 2024-2028.
According to TechSci Research report, “Hunter
Syndrome Treatment Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Hunter
Syndrome Treatment Market stood at USD 1055.37 million in 2022 and is
anticipated to grow with a CAGR of 5.02% in the forecast period, 2024-2028.
This can be attributed to global collaborations. International collaborations
between research institutions, pharmaceutical companies, and healthcare
organizations have facilitated the exchange of knowledge and expertise in the
field of Hunter syndrome treatment. These partnerships have accelerated the
development of new therapies and expanded their availability to a wider patient
base. Furthermore, efforts to expand access to Hunter syndrome treatments are
gaining traction. As awareness increases and more treatment options become
available, there is a growing focus on making these therapies accessible to
patients in regions with limited healthcare infrastructure. International
collaborations and partnerships are helping expand treatment access on a global
scale.
The growth of the Hunter Syndrome market was
significantly impacted by the COVID-19 pandemic. For instance, a study
published in BMC in September 2021 revealed that lysosomal storage diseases
(LSDs), including mucopolysaccharidosis II (MPS II or Hunter Syndrome), were
negatively affected by COVID-19, leading to disruptions in patients' access to
continuous care and therapy. These patients faced a higher risk of contracting
COVID-19 compared to the general population. Another study published in BMC in
October 2021 indicated that approximately 20% of patients receiving enzyme
replacement therapy (ERT) in a hospital setting experienced treatment
disruptions due to the pandemic. Consequently, delayed treatment services had a
detrimental impact on the market's growth during this period. However, as the
pandemic progressed, the market showed signs of recovery, reflected in the
increasing number of product developments and approvals. For instance, in
January 2021, GC Pharma obtained Japanese manufacturing and marketing approval
for Hunterase ICV (intracerebroventricular) injection of 15 mg as a treatment
for mucopolysaccharidosis type II (Hunter Syndrome). Several factors are contributing to the market's
growth, including rising government initiatives, the introduction of innovative
therapies, and robust pipelines for treating Hunter Syndrome. The increasing
burden of Hunter diseases and a growing patient population have led to
increased investment in research and drug discovery, expected to drive market
growth. For example, in September 2021, Takeda Pharmaceuticals entered into an
exclusive collaboration and license agreement with JCR Pharmaceuticals to commercialize
JR-141, an investigational next-generation recombinant fusion protein designed
to treat Hunter Syndrome. This collaboration covers regions outside of the
United States, including Canada, Europe, and other areas, excluding Japan and
specific Asia-Pacific countries. JCR received an upfront payment for this ex-US
license and is eligible for additional development and commercial milestones,
as well as tiered royalties on potential sales. Such developments are
anticipated to enhance the availability of drugs and therapies in the market,
thus bolstering growth over the forecast period.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Hunter Syndrome Treatment Market.”
Furthermore, the increasing focus on various research
and development activities by companies to launch new products for treating
Hunter diseases is a contributing factor. For instance, in September 2022,
AVROBIO Inc. announced the approval by the UK MHRA, Research Ethics Committee
(REC), and Health Research Authority (HRA) to initiate a Phase 1/2 clinical
trial of investigational autologous hematopoietic stem cell (HSC) gene therapy
for infants diagnosed with neuronopathic mucopolysaccharidosis/Hunter Disease. The market's growth is also supported by the
government and organizations' efforts to adopt various strategies, such as
collaborations and partnerships, to develop effective drugs and treatment
options. An example of this is the partnership between the National MPS Society
and Genetic Alliance with Luna in June 2022, aimed at accelerating the
development of therapies for Hunter Syndrome patients. In December 2021, these
organizations, in collaboration with Takeda Pharmaceutical Company Limited,
launched a digital drug discovery community to advance therapeutic interventions
for patients with mucopolysaccharidosis type II (MPS II), also known as Hunter
Syndrome. The Global Hunter Syndrome Treatment Market is
segmented into treatment, end user, regional distribution, and company. Based on its treatment, it is anticipated that the
Enzyme Replacement Therapy (ERT) sector will experience substantial growth in
the Hunter Syndrome Treatment Market during the projected period. This growth
is attributed to several factors, including the increased availability of
enzyme replacement therapies, heightened awareness, and less stringent
regulations concerning rare diseases. Enzyme replacement therapy (ERT) has become a standard
treatment for various rare diseases. It involves replacing the deficient or
absent enzyme with a functional recombinant version through intravenous
administration. For example, a study published in October 2021 highlighted the
effectiveness of pabinafusp alfa in addressing both somatic and CNS symptoms in
MPS-II patients, thanks to its ability to traverse the blood-brain barrier to
reach central nervous tissues. Consequently, the high efficacy and safety of
this innovative enzyme drug are expected to drive its adoption in Hunter
Syndrome treatment, thereby boosting market growth.
Based on end user, Hospitals and clinics are poised to
maintain their dominant position in the Global Hunter Syndrome Treatment Market
throughout the forecast years for several compelling reasons. First and
foremost, these healthcare facilities serve as the primary points of access for
patients seeking diagnosis, treatment, and ongoing care for Hunter Syndrome.
Their established infrastructure, specialized medical teams, and access to
cutting-edge medical technologies make hospitals and clinics the go-to destinations
for patients and their families. Furthermore, these institutions often
collaborate closely with pharmaceutical companies and research organizations to
stay at the forefront of treatment advancements, ensuring that patients receive
the most effective therapies available. Additionally, hospitals and clinics
benefit from their ability to offer comprehensive, multidisciplinary care,
addressing not only the physical symptoms of the disease but also the
psychological and emotional well-being of patients, which is vital in managing
a complex condition like Hunter Syndrome. As a result, their pivotal role in
providing holistic care and driving innovation positions them to remain
dominant players in the Hunter Syndrome Treatment Market in the foreseeable
future.
Major companies operating in Global Hunter
Syndrome Treatment Market are:
- Takeda Pharmaceutical Co Ltd
- F Hoffmann-La Roche AG
- Abbott Laboratories Inc
- Johnson & Johnson
- GSK PLC
- Bayer AG
- Novartis AG
- Pfizer Inc
- Zimmer Biomet Holdings Inc
- Sangamo Therapeutics, Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The future of the Global Hunter Syndrome Treatment
Market is filled with promise and innovation. Emerging trends, such as gene
therapy, personalized medicine, advanced ERTs, and improved treatment access,
are expected to reshape the treatment landscape and offer new hope to
individuals living with Hunter syndrome. As researchers, healthcare providers,
patient advocacy groups, and pharmaceutical companies collaborate to address
the challenges posed by this rare genetic disorder, the outlook for the Hunter
Syndrome Treatment Market remains optimistic, driven by a commitment to
improving the lives of those affected by this condition,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Hunter Syndrome Treatment Market By Treatment
(Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By End User
(Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Hunter Syndrome Treatment Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Hunter Syndrome Treatment Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com